SF
TGTX icon

Synovus Financial’s TG Therapeutics TGTX Stock Holding History

Synovus Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$415K Sell
11,500
-2,000
-15% -$65.9K ﹤0.01% 734
2025
Q2 		$486K Sell
13,500
-4,500
-25% -$168K 0.01% 670
2025
Q1 		$710K Sell
18,000
-1,500
-8% -$50.5K 0.01% 568
2024
Q4 		$587K Sell
19,500
-400
-2% -$11.5K 0.01% 601
2024
Q3 		$465K Buy
+19,900
New +$435K 0.01% 698

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Synovus Financial's TGTX Position: Q3 2025 in Review

Synovus Financial reduced its TG Therapeutics (TGTX) stake by 15% in Q3 2025, selling an estimated $65.9K and leaving 11,500 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #734.

Synovus Financial first reported a position in TGTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $710K in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Synovus Financial held 11,500 shares of TG Therapeutics worth $415K as of Q3 2025.
  • Synovus Financial sold 2,000 TG Therapeutics shares in Q3 2025, an estimated $65.9K.
  • TG Therapeutics made up ﹤0.01% of Synovus Financial's portfolio in Q3 2025, its #734 holding.
  • Synovus Financial first reported a position in TG Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Synovus Financial's TG Therapeutics position peaked at $710K in Q1 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.